HFSA

Beyond's analysis on HFSA

• 2026-10-10 — MannKind’s HFSA 2026 data show Furoscix ReadyFlow can manage edema outside the hospital, widening its market opportunity

Recent news mentioning HFSA

• 2026-10-10 — MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
• 2026-10-02 — Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
• 2026-09-29 — CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
• 2026-09-18 — HFSA's 2026 Annual Scientific Meeting to Feature Late-Breaking Trials That Could Reshape Heart Failure Treatment
• 2026-09-10 — New Study Links HFSA OMT-HF Education to Changes in Heart Failure Prescribing

Appears alongside

• MannKind
• ReadyFlow
• CKD

Browse the full archive →